Sharekhan

Brooks Laboratories Ltd

Mon 1/12/2025,10:44:33 | NSE : BROOKS

₹ 103.511.31 (1.28%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 103.99

Previous Close

₹ 102.20

Volume

2451

Mkt Cap ( Rs. Cr)

₹304.91

High

₹ 105.65

Low

₹ 102.85

52 Week High

₹ 198.86

52 Week Low

₹ 95.25

Book Value Per Share

₹ 21.19

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Brooks Laboratories Ltd

Your Vote -

Buy

22.22%

Hold

5.56%

Sell

72.22%

22.22%

36 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

39%

Sell Order Quantity

61%

Bid Price

Qty

102.76

15

103.00

1

103.00

22

103.00

1

103.00

1

Bid Total

11552

Bid Price

Qty

103.13

1

103.00

8

103.00

5

103.00

5

103.00

21

Bid Total

18328

Option Chain

Analyzes market sentiment, predicts Brooks Laboratories Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Brooks Laboratories - Copy of Newspaper Publication

    15 Nov 2025, 2:45PM Brooks Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
  • Brooks Laboratories Q2 net profit zooms 133.33% at Rs 2.24 cr

    14 Nov 2025, 8:56PM The company reported standalone net profit of Rs 2.24 crore for the quarter ended September 30, 2025 as compared to Rs 0.96 crore in the same period l
  • Brooks Laboratories - Outcome of Board Meeting

    14 Nov 2025, 7:56PM Brooks Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
  • Brooks Laboratories - Board Meeting Outcome for Outcome Of The Board Meeting Held On Friday, 14Th November 2025.

    14 Nov 2025, 7:17PM Outcome of the Board Meeting held on Friday, 14th November 2025.
  • Brooks Laboratories - Results For Quarter And Half Year Ended 30Th September 2025

    14 Nov 2025, 7:00PM Approved Results for quarter and half year ended 30th September 2025 at Board Meeting held on Friday 14th November, 2025
  • Brooks Laboratories - Credit Rating

    12 Nov 2025, 12:57PM Brooks Laboratories Limited has informed the Exchange about Credit Rating
  • Brooks Laboratories - Announcement under Regulation 30 (LODR)-Credit Rating

    12 Nov 2025, 12:37PM Intimation of Credit Rating under Regulation 30 of SEBI(LODR) 2015.
  • Brooks Laboratories - Board Meeting Intimation for Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Reg

    7 Nov 2025, 12:56PM Brooks Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider
  • Brooks Laboratories - Resignation

    16 Oct 2025, 9:03PM Brooks Laboratories Limited has informed the Exchange regarding Resignation of Senior Management Personnel of the company w.e.f. October 16, 2025.
  • Brooks Laboratories - Announcement under Regulation 30 (LODR)-Change in Management

    16 Oct 2025, 8:55PM Change in Senior Management Personnel.
  • Brooks Laboratories has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2025

    16 Oct 2025, 1:30PM As of September 2025, 52.62% is owned by Indian Promoters and 47.38% by Public. <p align=justify> Top five Promoters holding highest number of shares
  • Brooks Laboratories - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    9 Oct 2025, 5:37PM Brooks Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Brooks Laboratories - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    9 Oct 2025, 5:13PM Compliance Certificate under Regulation 74(5) of SEBI(Depositories and Participants) Regulations 2018 for the quarter ended September 30, 2025.
  • Brooks Laboratories - Shareholders meeting

    27 Sep 2025, 5:20PM Brooks Laboratories Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 26, 2024
  • Brooks Laboratories - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    27 Sep 2025, 5:05PM Scrutinizer Report along with voting results for the AGM held on September 26, 2025
  • Brooks Laboratories - Trading Window

    27 Sep 2025, 1:44PM Brooks Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulatio
  • Brooks Laboratories - 'Merger Of Brooks Steriscience Limited (BSL), A Joint Venture/Associate Of The Company, Through A Comp

    26 Sep 2025, 11:22PM Merger of BSL through a composite scheme of arrangement and amalgamation.
  • Brooks Laboratories - Updates

    26 Sep 2025, 11:18PM Brooks Laboratories Limited has informed the Exchange regarding 'Merger of Brooks Steriscience Limited (BSL), a Joint Venture/Associate of the Company
  • Brooks Laboratories - Appointment

    26 Sep 2025, 11:03PM Brooks Laboratories Limited has informed the Exchange regarding Appointment of M/s. Sharma Sarin & Associates, as the Secretarial Auditor of the Compa
  • Brooks Laboratories - Announcement under Regulation 30 (LODR)-Change in Management

    26 Sep 2025, 10:36PM Appointment of Secretarial Auditor of the Company for 5 consecutive years from 2025-2026 to 2029-2030.
  • Brooks Laboratories - Shareholders meeting

    26 Sep 2025, 7:20PM Brooks Laboratories Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 26, 2025
  • Brooks Laboratories - Shareholder Meeting / Postal Ballot-Outcome of AGM

    26 Sep 2025, 7:09PM Pursuant to Regulation 30 of SEBI (LODR) 2015, please find enclosed herewith a summary of the proceedings of the 23rd AGM.
  • Brooks Laboratories - 'Merger Of Brooks Steriscience Limited (BSL), A Joint Venture/Associate Of The Company, Through A Comp

    26 Sep 2025, 11:22PM Merger of BSL through a composite scheme of arrangement and amalgamation.
  • Brooks Laboratories - Updates

    10 Sep 2025, 12:11PM Brooks Laboratories Limited has informed the Exchange regarding 'Intimation Of Record Date, E-Voting Dates And Book Closure Date'.
  • Brooks Laboratories - Intimation Of Record Date, E-Voting Dates And Book Closure Date

    10 Sep 2025, 11:50AM Intimation of Record Date, E-Voting Dates and Book Closure Date.
  • Brooks Laboratories - Letter To The Shareholders - Annual Report For The FY 2024-25.

    4 Sep 2025, 9:48PM Letter to the Shareholders - Annual Report for the FY 2024-2025.
  • Brooks Laboratories - Shareholder Meeting- AGM On 26Th September 2025.

    4 Sep 2025, 9:06PM Notice of 23rd Annual General Meeting of the Company to be held on Friday, 26th September 2025 at 9:00 A.M through VC/OAVM.
  • Brooks Laboratories - Reg. 34 (1) Annual Report.

    4 Sep 2025, 8:53PM Pursuant to Regulation 34 read with Regulation 30 of SEBI Listing Regulations, we are enclosing herewith the following: 1. Notice of the AGM.2. Annual
  • Brooks Laboratories - Copy of Newspaper Publication

    2 Sep 2025, 3:04PM Newspaper Advertisement regarding the 23rd Annual General Meeting of the Company to be held on Friday, September 26, 2025 through Video Conferencing a
  • Brooks Laboratories - Amendment to AOA/MOA

    1 Sep 2025, 12:10PM Brooks Laboratories Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company.
  • Brooks Laboratories - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association

    1 Sep 2025, 12:01PM This is to inform you that the Board of Directors at its meeting held on 1st September 2025, has approved alteration in object clause of Memorandum of

Key fundamentals

Evaluate the intrinsic value of Brooks Laboratories Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 121.133 74.5735 62.4424 69.9259 72.3712
Liabilities 121.133 74.5735 62.4424 69.9259 72.3712
Equity 29.4572 26.2467 24.7028 24.7028 24.7028
Gross Profit 4.9743 3.2173 -5.8143 1.8744 0.7638
Net Profit 3.0522 1.5287 -8.1912 0.666 -15.5876
Cash From Operating Activities 2.6263 -9.6806 0.5622 3.1235 -0.8986
NPM(%) 3.69 1.92 -14.74 0.86 -20.17
Revenue 82.5568 79.4861 55.538 76.9672 77.2469
Expenses 77.5825 76.2688 61.3523 75.0928 76.4831
ROE(%) 4.88 2.44 -13.12 1.06 -24.97

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Brooks Laboratories Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 797.85 0.62 0.00 59.98 301.39 0.63
Lotus Eye Hospital and Institute Ltd 105.11 -0.51 328.47 218.57 3.55 0.00
Vaishali Pharma Ltd 8.83 0.46 0.00 1371.16 3.13 0.00
Astec Lifesciences Ltd 825.25 -1.51 0.00 206.12 -604.77 0.00

Company Info

Our Company was incorporated vide a Certificate of Incorporation dated January 23, 2002 bearing CIN No. U24232PB2002PLC24910 under the Companies Act 1956 with the name `Brooks Laboratories Limited' by our promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan. We received our certificate of commencement of business on February 19, 2002, from the Registrar of Companies, Punjab, Himachal Pradesh & Chandigarh at Jalandhar. Our Company was initially promoted for manufacturing of latest molecules in Injectables, tablets and dry syrups for the domestic customers. Our Company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development ("R&D") centre at Baddi, Himachal Pradesh. Our Company started its commercial production in the month of June 2006. Our Company became profitable from the very first year of its production. This facility at Baddi is WHO-GMP and ISO 9001:2008 certified. The facility focuses on developing latest molecules in the niche segments and then selling it to various pharmaceutical marketing Companies. Before staring our company, our promoters were engaged in manufacturing of Pharmaceutical Formulations in their partnership firm namely Brooks Pharmaceuticals. The firm had a manufacturing facility at F-94, Industrial Area, Phase 7, Mohali, Punjab. The factory at Mohali had annual installed capacity of 30 Lacs Injectables, 300 Lacs Tablets and 15 Lacs Dry Syrups. Our promoters had a successful track record of running the manufacturing of formulations in the aforesaid firm, profitably for over 6 years. In order to take an advantage of the growing market and avail the tax and other benefits that were made available by the Government to set up a manufacturing facility at Baddi, our promoters decided incorporate our company Brooks Laboratories Ltd and set up a bigger and more sophisticated unit at Baddi, in Himachal Pradesh. Subsequently, the firm was dissolved in the month of December 2008. Further in years 2007 and 2008 to have a smooth transition from Brook Pharmaceuticals to Brooks Laboratories Ltd., Our Company paid/settled some dues to Creditors and Lenders of Brooks Pharmaceuticals aggregating to Rs. 151.79 Lacs. Later on to settle the above our Company purchased on book value certain assets (Fixed assets & Stocks) aggregating to Rs. 113.27 Lacs and received an aggregate sum of Rs. 38.52 Lacs from M/s. Brooks Pharmaceuticals, a partnership firm promoted by our Promoters, Mr. Atul Ranchal and Mr. Rajesh Mahajan. Key Events and Milestones January 23, 2002 Incorporation of Brooks Laboratories Limited. February 19,2002 Received certificate for commencement of business May 5, 2005 Commenced setting up of manufacturing facility at Baddi, Himachal Pradesh. April 10,2006 Manufacturing drugs license issued by the State Drugs Controlling and Licensing Authority, HP. April 30, 2005 Commissioning of R&D centre at Baddi May 20,2006 Completion of Commissioning of plant for manufacture of Tablets, capsules, Injections, Oral Liquids etc. May 30, 2006 Start of commercial production June 1, 2006 First PPI Formulation developed by the Company. October 27,2006 Obtained Import license from Drugs Controller General of India under the Drugs Act 1940 and Drugs Rules. August 02, 2007 Received an AS/NZS ISO 9001:2000 Certificate from SAI Global Certification Services Pty Limited, Australia. April 30, 2008* Takeover of some of the Assets of M/s Brooks Pharmaceuticals, a partnership firm of Our Promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan by our Company. December 30, 2008 Dissolution of M/s Brooks Pharmaceuticals, a partnership firm of Our Promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan. January 06,2009 Micro Small Medium Enterprise (MSME) Registration Certificate issued by Directorate of Industries for Manufacturing/Assembling Injections, Capsules & Tabulates (Single Window Clearance Agency). April 7,2010 The manufacturing facility at Baddi was certified as WHO GMP compliant by Department of Health & Family Welfare, HP. July 27,2010 Received an ISO 9001:2008 Certificate from UKAS Quality Management, URS & IAF. 2012 --Registered Office of the Company has been shifted to Village Kishanpura, Nalagarh Road, Baddi, Distt. Solan, H.P 2013 -Mr. Bhaskar Sharma has been appointed as Additional Independent Director of the company. 2014 - Ms.Sonia Gupta has been appointed as Independent Director of the Company. 2015 -Brooks Laboratories - Shifting of Corporate Office to 5th Floor, Next to Hotel Courtyard Marriott, Andheri Kurla Road, Mumbai - 400093. 2016 -Brooks Laboratories gets manufacturing licence for Gujarat facility. 2023 -The company issued rights shares of Rs. 10 in the ratio of 1:16 at a premium of Rs. 65 per share.

Our Company was incorporated vide a Certificate of Incorporation dated January 23, 2002 bearing CIN No. U24232PB2002PLC24910 under the Companies Act 1956 with the name `Brooks Laboratories Limited' by our promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan. We received our certificate of commencement of business on February 19, 2002, from the Registrar of Companies, Punjab, Himachal Pradesh & Chandigarh at Jalandhar. Our Company was initially promoted for manufacturing of latest molecules in Injectables, tablets and dry syrups for the domestic customers. Our Company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development ("R&D") centre at Baddi, Himachal Pradesh. Our Company started its commercial production in the month of June 2006. Our Company became profitable from the very first year of its production. This facility at Baddi is WHO-GMP and ISO 9001:2008 certified. The facility focuses on developing latest molecules in the niche segments and then selling it to various pharmaceutical marketing Companies. Before staring our company, our promoters were engaged in manufacturing of Pharmaceutical Formulations in their partnership firm namely Brooks Pharmaceuticals. The firm had a manufacturing facility at F-94, Industrial Area, Phase 7, Mohali, Punjab. The factory at Mohali had annual installed capacity of 30 Lacs Injectables, 300 Lacs Tablets and 15 Lacs Dry Syrups. Our promoters had a successful track record of running the manufacturing of formulations in the aforesaid firm, profitably for over 6 years. In order to take an advantage of the growing market and avail the tax and other benefits that were made available by the Government to set up a manufacturing facility at Baddi, our promoters decided incorporate our company Brooks Laboratories Ltd and set up a bigger and more sophisticated unit at Baddi, in Himachal Pradesh. Subsequently, the firm was dissolved in the month of December 2008. Further in years 2007 and 2008 to have a smooth transition from Brook Pharmaceuticals to Brooks Laboratories Ltd., Our Company paid/settled some dues to Creditors and Lenders of Brooks Pharmaceuticals aggregating to Rs. 151.79 Lacs. Later on to settle the above our Company purchased on book value certain assets (Fixed assets & Stocks) aggregating to Rs. 113.27 Lacs and received an aggregate sum of Rs. 38.52 Lacs from M/s. Brooks Pharmaceuticals, a partnership firm promoted by our Promoters, Mr. Atul Ranchal and Mr. Rajesh Mahajan. Key Events and Milestones January 23, 2002 Incorporation of Brooks Laboratories Limited. February 19,2002 Received certificate for commencement of business May 5, 2005 Commenced setting up of manufacturing facility at Baddi, Himachal Pradesh. April 10,2006 Manufacturing drugs license issued by the State Drugs Controlling and Licensing Authority, HP. April 30, 2005 Commissioning of R&D centre at Baddi May 20,2006 Completion of Commissioning of plant for manufacture of Tablets, capsules, Injections, Oral Liquids etc. May 30, 2006 Start of commercial production June 1, 2006 First PPI Formulation developed by the Company. October 27,2006 Obtained Import license from Drugs Controller General of India under the Drugs Act 1940 and Drugs Rules. August 02, 2007 Received an AS/NZS ISO 9001:2000 Certificate from SAI Global Certification Services Pty Limited, Australia. April 30, 2008* Takeover of some of the Assets of M/s Brooks Pharmaceuticals, a partnership firm of Our Promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan by our Company. December 30, 2008 Dissolution of M/s Brooks Pharmaceuticals, a partnership firm of Our Promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan. January 06,2009 Micro Small Medium Enterprise (MSME) Registration Certificate issued by Directorate of Industries for Manufacturing/Assembling Injections, Capsules & Tabulates (Single Window Clearance Agency). April 7,2010 The manufacturing facility at Baddi was certified as WHO GMP compliant by Department of Health & Family Welfare, HP. July 27,2010 Received an ISO 9001:2008 Certificate from UKAS Quality Management, URS & IAF. 2012 --Registered Office of the Company has been shifted to Village Kishanpura, Nalagarh Road, Baddi, Distt. Solan, H.P 2013 -Mr. Bhaskar Sharma has been appointed as Additional Independent Director of the company. 2014 - Ms.Sonia Gupta has been appointed as Independent Director of the Company. 2015 -Brooks Laboratories - Shifting of Corporate Office to 5th Floor, Next to Hotel Courtyard Marriott, Andheri Kurla Road, Mumbai - 400093. 2016 -Brooks Laboratories gets manufacturing licence for Gujarat facility. 2023 -The company issued rights shares of Rs. 10 in the ratio of 1:16 at a premium of Rs. 65 per share.

Read More

Parent Organisation

Brooks Laboratories Ltd.

Founded

23/01/2002

Managing Director

NSE Symbol

BROOKSEQ

FAQ

The current price of Brooks Laboratories Ltd is ₹ 103.51.

The 52-week high for Brooks Laboratories Ltd is ₹ 105.65 and the 52-week low is ₹ 102.85.

The market capitalization of Brooks Laboratories Ltd is currently ₹ 304.91. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Brooks Laboratories Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Brooks Laboratories Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Brooks Laboratories Ltd shares.

The CEO of Brooks Laboratories Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT